Biohaven Ltd. Common Shares (BHVN)

About BHVN

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

274

Website

www.biohaven.com/

Fundamentals

1-day range

$14.94$16.34

Market cap

$2.01B

P/E (trailing)

—

P/E (forward)

-7.76

EPS (trailing)

$-5.67

Dividend yield

—

Beta

3.11

Avg. volume

3.03M

Forecasts

15 analyst ratings

Biohaven Ltd. Common Shares Competitors

Chosen by industry and closest market cap.

• BHVN

  Biohaven Ltd. Common Shares

  $15.42

  ▼ 4.37%
  Market cap $2.01BP/E —
  $7.48$18.57
• ZBIO

  Zenas BioPharma Inc. Common Stock

  $31.29

  ▼ 4.08%
  Market cap $1.97BP/E —
  $13.5$44.6
• MLYS

  Mineralys Therapeutics Inc. Common Stock

  $25.59

  ▼ 1.61%
  Market cap $2.13BP/E —
  $14.94$47.65
• AUPH

  Aurinia Pharmaceuticals Inc Ordinary Shares

  $16.3

  ▼ 1.09%
  Market cap $1.89BP/E 6.39
  $10.34$19.25
• NBTX

  Nanobiotix S.A. American Depositary Shares

  $41.28

  ▼ 8.59%
  Market cap $1.88BP/E —
  $7.02$47.66
• URGN

  UroGen Pharma Ltd. Ordinary Shares

  $43.61

  ▼ 4.15%
  Market cap $1.88BP/E —
  $15.86$50.81
• NUVB

  Nuvation Bio Inc. Class A Common Stock

  $6.67

  ▼ 4.65%
  Market cap $2.14BP/E —
  $2.87$9.75

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Why Biohaven Stock Was Rocking the Market This Week
  Yahoo · 8/28/2026
• Slate Medicines Starts Migraine Treatment Study
  Yahoo · 8/27/2026
• SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race
  Yahoo · 8/27/2026
• Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More
  SeekingAlpha · 8/27/2026
• BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program
  Yahoo · 8/27/2026
• Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels
  SeekingAlpha · 8/27/2026
• Why Is Biohaven Stock Soaring Wednesday?
  benzinga · 8/26/2026
• BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout
  Yahoo · 8/26/2026
• Why Is Biohaven Stock Soaring Wednesday?
  Benzinga · 8/26/2026

• Antonijevic Irina · April 28, 2026 · Grant

  68.7K
• Mehta Kishan · April 28, 2026 · Grant

  68.7K
• Heffernan Michael Thomas · April 28, 2026 · Grant

  68.7K
• Gregory Bailey · April 28, 2026 · Grant

  68.7K
• HUGIN ROBERT J · April 28, 2026 · Grant

  68.7K
• GREGORY JULIA P · April 28, 2026 · Grant

  68.7K
• John W. Childs · April 28, 2026 · Grant

  68.7K
• Mehta Kishan · March 17, 2026 · Gift

  17.3K